8.471
Precedente Chiudi:
$8.685
Aprire:
$8.9709
Volume 24 ore:
55,115
Relative Volume:
0.49
Capitalizzazione di mercato:
$26.93M
Reddito:
-
Utile/perdita netta:
$-68.80M
Rapporto P/E:
-7.2402
EPS:
-1.17
Flusso di cassa netto:
$-59.06M
1 W Prestazione:
+6.55%
1M Prestazione:
+19.99%
6M Prestazione:
+2,241%
1 anno Prestazione:
+1,336%
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Confronta PASG con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PASG
Passage Bio Inc
|
8.471 | 27.61M | 0 | -68.80M | -59.06M | -1.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-29 | Ripresa | Wedbush | Outperform |
2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
2022-01-19 | Downgrade | Goldman | Buy → Neutral |
2021-07-01 | Iniziato | Raymond James | Outperform |
2021-06-15 | Iniziato | BTIG Research | Buy |
2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
2021-02-04 | Iniziato | Guggenheim | Buy |
2021-01-25 | Iniziato | Wedbush | Outperform |
2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
2020-12-11 | Iniziato | Citigroup | Neutral |
2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
2020-06-25 | Downgrade | Goldman | Buy → Neutral |
2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
2020-03-24 | Iniziato | Cowen | Outperform |
2020-03-24 | Iniziato | Goldman | Buy |
2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
Why Passage Bio Inc. stock could rally in 2025July 2025 Breakouts & Safe Capital Growth Tips - newser.com
What’s next for Passage Bio Inc. stock price2025 Stock Rankings & Safe Entry Trade Reports - newser.com
What the charts say about Passage Bio Inc. todayWeekly Risk Report & High Yield Equity Trading Tips - newser.com
How to build a custom watchlist for Passage Bio Inc.July 2025 Drop Watch & Free Weekly Watchlist of Top Performers - newser.com
Full technical analysis of Passage Bio Inc. stockWeekly Profit Analysis & Real-Time Chart Pattern Alerts - newser.com
Key resistance and support levels for Passage Bio Inc.July 2025 Sentiment & Detailed Earnings Play Strategies - newser.com
What analysts say about Passage Bio Inc stockTechnical Pattern Recognition & Consistently Superior Profits - earlytimes.in
Passage Bio Inc. stock daily chart insightsTake Profit & Weekly Watchlist of Top Performers - newser.com
How buybacks impact Passage Bio Inc. stock valueTrade Risk Report & AI Driven Stock Reports - newser.com
Passage Bio Inc Stock Analysis and ForecastTrend Following Strategies & Rapid Portfolio Expansion - earlytimes.in
Is it too late to sell Passage Bio Inc.Bull Run & Weekly High Momentum Picks - newser.com
Is Passage Bio Inc. stock poised for growthWeekly Risk Report & Safe Capital Preservation Plans - newser.com
Is Passage Bio Inc. reversing from oversold territory2025 Pullback Review & High Accuracy Trade Signal Alerts - newser.com
Passage Bio (NASDAQ:PASG) Trading Up 1.8% – Time to Buy? - Defense World
Is Passage Bio Inc a good long term investmentMACD Histogram Signals & Investment Risk Management Tips - earlytimes.in
How institutional ownership impacts Passage Bio Inc. stockWeekly Trend Report & Safe Swing Trade Setups - newser.com
GM1 Gangliosidosis Market: Epidemiology, Therapies, Companies – DelveInsight | Featuring Passage Bio Inc., Gain Therapeutics, Sio Gene Therapies - The Globe and Mail
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Retail Surge: Can Passage Bio Inc ride the EV waveWeekly Trading Summary & High Accuracy Trade Signal Alerts - خودرو بانک
Can machine learning forecast Passage Bio Inc. recoveryJuly 2025 Final Week & Free Expert Approved Momentum Trade Ideas - newser.com
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Passage Bio Inc Azioni (PASG) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Lynx1 Capital Management LP | 10% Owner |
Sep 15 '25 |
Buy |
6.99 |
11,900 |
83,175 |
623,704 |
Lynx1 Capital Management LP | 10% Owner |
Sep 11 '25 |
Buy |
6.96 |
325 |
2,261 |
592,021 |
Lynx1 Capital Management LP | 10% Owner |
Jul 24 '25 |
Buy |
5.71 |
66,423 |
379,455 |
591,696 |
Lynx1 Capital Management LP | 10% Owner |
Jul 23 '25 |
Buy |
5.74 |
49,302 |
283,033 |
525,273 |
Lynx1 Capital Management LP | 10% Owner |
Jul 22 '25 |
Buy |
5.44 |
13,123 |
71,338 |
475,971 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):